MX356493B - Composicion farmaceutica que comprende (1r.4r)-6´-fluoro-n,n-dimet il-4-fenil-4´,9´-dihidro-3´h-espiro[ciclohexan-1,1´-pirano[3,4,b] indol]-4-amina y un nsar. - Google Patents
Composicion farmaceutica que comprende (1r.4r)-6´-fluoro-n,n-dimet il-4-fenil-4´,9´-dihidro-3´h-espiro[ciclohexan-1,1´-pirano[3,4,b] indol]-4-amina y un nsar.Info
- Publication number
- MX356493B MX356493B MX2014013028A MX2014013028A MX356493B MX 356493 B MX356493 B MX 356493B MX 2014013028 A MX2014013028 A MX 2014013028A MX 2014013028 A MX2014013028 A MX 2014013028A MX 356493 B MX356493 B MX 356493B
- Authority
- MX
- Mexico
- Prior art keywords
- pyrano
- indol
- spiro
- dihydro
- cyclohexane
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente invención se relaciona con una composición farmacéutica que comprende un primer ingrediente farmacológicamente activo, seleccionado de (1R,4R)-6´-fluoro-N,N-d imetil-4-fenil-4´,9´-dihidro-3´H-espiro[ciclohexan-1,1´-pirano[3, 4-b]indol]-4-amina y las sales fisiológicamente aceptables del mismo, y un segundo ingrediente farmacológicamente activo, el cual es un fármaco antirreumático no esteroideo seleccionado del grupo que consiste de indometacina, diclofenaco, sulindaco, tolmetina, zomepiraco, aclofenaco, bumadizona, etolodaco, lonazolaco, fentiazaco, acemetacina, difenpiramida, oxamatacin, proglumetacina, keterolaco, aceclofenaco, bufexamaco, ácido mefenámico, ácido tolfenámico, ácido flufenámico, ácido meclofenámico y las sales fisiológicamente aceptables de los mismos. Figura 1.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12003895 | 2012-05-18 | ||
| PCT/EP2013/001470 WO2013170971A1 (en) | 2012-05-18 | 2013-05-16 | Pharmaceutical composition comprising (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano [3,4,b]indol]-4-amine and a nsar |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014013028A MX2014013028A (es) | 2015-02-04 |
| MX356493B true MX356493B (es) | 2018-05-31 |
Family
ID=48520892
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014013028A MX356493B (es) | 2012-05-18 | 2013-05-16 | Composicion farmaceutica que comprende (1r.4r)-6´-fluoro-n,n-dimet il-4-fenil-4´,9´-dihidro-3´h-espiro[ciclohexan-1,1´-pirano[3,4,b] indol]-4-amina y un nsar. |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US8912226B2 (es) |
| EP (1) | EP2849747B1 (es) |
| JP (1) | JP6116678B2 (es) |
| CN (1) | CN104284660A (es) |
| AU (1) | AU2013262077B2 (es) |
| BR (1) | BR112014028566A2 (es) |
| CA (1) | CA2873867A1 (es) |
| CY (1) | CY1119781T1 (es) |
| DK (1) | DK2849747T3 (es) |
| EA (1) | EA027145B1 (es) |
| ES (1) | ES2658217T3 (es) |
| HR (1) | HRP20171725T1 (es) |
| HU (1) | HUE034658T2 (es) |
| IL (1) | IL235653B (es) |
| LT (1) | LT2849747T (es) |
| MX (1) | MX356493B (es) |
| NO (1) | NO2849747T3 (es) |
| PL (1) | PL2849747T3 (es) |
| PT (1) | PT2849747T (es) |
| RS (1) | RS56788B1 (es) |
| SI (1) | SI2849747T1 (es) |
| WO (1) | WO2013170971A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201642853A (zh) | 2015-01-23 | 2016-12-16 | 歌林達有限公司 | 用於治療肝功能之損傷及/或腎功能之損傷個體疼痛之西博帕多(Cebranopadol) |
| WO2016168388A2 (en) | 2015-04-14 | 2016-10-20 | Palatin Technologies, Inc. | Therapies for obesity, diabetes and related indications |
| AU2017226830B2 (en) | 2016-02-29 | 2021-06-24 | Grünenthal GmbH | Titration of cebranopadol |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3273329D1 (en) | 1981-06-26 | 1986-10-23 | Upjohn Co | Analgesic process and composition |
| US4389393A (en) | 1982-03-26 | 1983-06-21 | Forest Laboratories, Inc. | Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose |
| US4404208A (en) * | 1982-06-30 | 1983-09-13 | E. I. Du Pont De Nemours And Company | Analgesic mixture of nalbuphine and tiflamizole |
| US4612008A (en) | 1983-05-11 | 1986-09-16 | Alza Corporation | Osmotic device with dual thermodynamic activity |
| US4765989A (en) | 1983-05-11 | 1988-08-23 | Alza Corporation | Osmotic device for administering certain drugs |
| US4783337A (en) | 1983-05-11 | 1988-11-08 | Alza Corporation | Osmotic system comprising plurality of members for dispensing drug |
| CA2058754C (en) | 1989-05-22 | 2002-02-19 | Hubertus L. Regtop | Divalent metal salts of indomethacin |
| US5472711A (en) | 1992-07-30 | 1995-12-05 | Edward Mendell Co., Inc. | Agglomerated hydrophilic complexes with multi-phasic release characteristics |
| US5330761A (en) | 1993-01-29 | 1994-07-19 | Edward Mendell Co. Inc. | Bioadhesive tablet for non-systemic use products |
| US5455046A (en) | 1993-09-09 | 1995-10-03 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems for insoluble drugs |
| US5399362A (en) | 1994-04-25 | 1995-03-21 | Edward Mendell Co., Inc. | Once-a-day metoprolol oral dosage form |
| US5914129A (en) | 1996-07-23 | 1999-06-22 | Mauskop; Alexander | Analgesic composition for treatment of migraine headaches |
| DE50104197D1 (de) | 2000-12-28 | 2004-11-25 | Fresenius Kabi Austria Gmbh Gr | Stabile Infusionslösung von Diclofenac-Salzen, deren Herstellung und Verwendung |
| SI1374906T1 (sl) | 2002-06-17 | 2007-10-31 | Chiesi Farma Spa | Postopek za pripravo inkluzijskih spojin piroksakama: beta-ciklodekstrina |
| DE10252667A1 (de) * | 2002-11-11 | 2004-05-27 | Grünenthal GmbH | Spirocyclische Cyclohexan-Derivate |
| DE10257824B4 (de) | 2002-12-10 | 2004-11-11 | Kochem, Hans-Günter, Dr. | Zusammensetzung zur Schmerzbehandlung, insbesondere zur Behandlung von Gelenkschmerzen |
| US20100297252A1 (en) | 2003-03-03 | 2010-11-25 | Elan Pharma International Ltd. | Nanoparticulate meloxicam formulations |
| US7132452B2 (en) | 2003-03-10 | 2006-11-07 | Fang-Yu Lee | Topical formulation having effects on alleviating pain/inflammation caused by herpes virus infection |
| DE10360792A1 (de) | 2003-12-23 | 2005-07-28 | Grünenthal GmbH | Spirocyclische Cyclohexan-Derivate |
| CN101198606A (zh) * | 2005-06-17 | 2008-06-11 | 辉瑞有限公司 | 作为ORL1-受体拮抗剂的α-(芳基-或杂芳基-甲基-)-β哌啶子基丙酰胺化合物 |
| PL2012763T3 (pl) * | 2006-04-28 | 2011-08-31 | Gruenenthal Gmbh | Kombinacja farmaceutyczna zawierająca 3-(3-dimetyloamino-1-etylo-2-metylo-propylo)-fenol i NSAID |
| CN101147735A (zh) | 2006-09-19 | 2008-03-26 | 沈阳华泰药物研究有限公司 | 注射用药物组合物及其药盒 |
| DE102006046745A1 (de) | 2006-09-29 | 2008-04-03 | Grünenthal GmbH | Gemischte ORL1/µ-Agonisten zur Behandlung von Schmerz |
| DE102006056458A1 (de) | 2006-11-28 | 2008-05-29 | Grünenthal GmbH | Arzneimittelzubereitung von Tramadol und Acetaminophen |
| AU2008310114B2 (en) * | 2007-10-09 | 2014-01-16 | Merck Patent Gmbh | Pharmaceutical compositions containing benfotiamine and one or more pharmaceutically active agents for the treatment of pain conditions of neuropathic origin |
| CN100560061C (zh) | 2008-06-20 | 2009-11-18 | 海南锦瑞制药股份有限公司 | 一种氯诺昔康冻干粉针剂及其制备方法 |
| HUE043278T2 (hu) * | 2008-09-05 | 2019-08-28 | Gruenenthal Gmbh | 3-(3-dimetilamino-1-etil-2-metil-propil)-fenolt és pregabalint vagy gabapentint tartalmazó gyógyszerkombináció |
| PE20110305A1 (es) * | 2008-09-05 | 2011-06-15 | Gruenenthal Chemie | Combinacion farmaceutica que contiene el 6-dimetilaminometil-1-(3-metoxi-fenil)-ciclohexano-1,3-diol y un nsaid |
| SI2600851T1 (en) * | 2010-08-04 | 2018-07-31 | Gruenenthal Gmbh | PHARMACEUTICAL FORM OF DOSAGE COVERING 6'-FLUORO- (N-METHYLLINE N, N-DIMETHYL-4-PHENYL-4 ', 9'-DIHYDRO-3'H-SPIRO- (CYCLOHEXANE-1,1'- PIRANO (3,4, B) INDOL) -4-AMIN, FOR NON-PROPHETIC DISEASE TREATMENT |
| PE20131106A1 (es) * | 2010-08-04 | 2013-10-17 | Gruenenthal Chemie | Aucforma de dosificacion farmaceutica que comprende 6'-fluoro-(n-metil- o n,n-dimetil)-4-fenil-4',9'-dihidro-3'h-espiro[ciclohexan-1,1'-pirano[3,4,b]indol]-4-amina |
| ES2553742T3 (es) * | 2010-08-04 | 2015-12-11 | Grünenthal GmbH | Forma de dosificación farmacéutica que comprende 6'-fluor-(N-metil- o N,N-dimetil)-4-fenil-4',9'-dihidro-3'H-espiro[ciclohexano-1,1'-pirano[3,4,b]indol]-4-amina |
-
2013
- 2013-05-13 US US13/892,732 patent/US8912226B2/en active Active
- 2013-05-16 WO PCT/EP2013/001470 patent/WO2013170971A1/en not_active Ceased
- 2013-05-16 CN CN201380025645.4A patent/CN104284660A/zh active Pending
- 2013-05-16 SI SI201330926T patent/SI2849747T1/en unknown
- 2013-05-16 RS RS20180063A patent/RS56788B1/sr unknown
- 2013-05-16 HU HUE13725072A patent/HUE034658T2/hu unknown
- 2013-05-16 MX MX2014013028A patent/MX356493B/es active IP Right Grant
- 2013-05-16 CA CA2873867A patent/CA2873867A1/en not_active Abandoned
- 2013-05-16 AU AU2013262077A patent/AU2013262077B2/en not_active Ceased
- 2013-05-16 HR HRP20171725TT patent/HRP20171725T1/hr unknown
- 2013-05-16 EP EP13725072.6A patent/EP2849747B1/en not_active Not-in-force
- 2013-05-16 DK DK13725072.6T patent/DK2849747T3/en active
- 2013-05-16 ES ES13725072.6T patent/ES2658217T3/es active Active
- 2013-05-16 LT LTEP13725072.6T patent/LT2849747T/lt unknown
- 2013-05-16 PT PT137250726T patent/PT2849747T/pt unknown
- 2013-05-16 EA EA201401270A patent/EA027145B1/ru not_active IP Right Cessation
- 2013-05-16 JP JP2015511957A patent/JP6116678B2/ja active Active
- 2013-05-16 NO NO13725072A patent/NO2849747T3/no unknown
- 2013-05-16 BR BR112014028566A patent/BR112014028566A2/pt active Search and Examination
- 2013-05-16 PL PL13725072T patent/PL2849747T3/pl unknown
-
2014
- 2014-11-12 IL IL235653A patent/IL235653B/en active IP Right Grant
-
2018
- 2018-01-16 CY CY20181100051T patent/CY1119781T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2658217T3 (es) | 2018-03-08 |
| IL235653B (en) | 2018-08-30 |
| EP2849747B1 (en) | 2017-11-01 |
| PT2849747T (pt) | 2018-02-07 |
| MX2014013028A (es) | 2015-02-04 |
| IL235653A0 (en) | 2015-01-29 |
| EA027145B1 (ru) | 2017-06-30 |
| AU2013262077B2 (en) | 2017-10-26 |
| US20130317075A1 (en) | 2013-11-28 |
| JP6116678B2 (ja) | 2017-04-19 |
| HUE034658T2 (hu) | 2018-02-28 |
| CY1119781T1 (el) | 2018-06-27 |
| EA201401270A1 (ru) | 2016-05-31 |
| NO2849747T3 (es) | 2018-03-31 |
| CA2873867A1 (en) | 2013-11-21 |
| EP2849747A1 (en) | 2015-03-25 |
| LT2849747T (lt) | 2018-01-25 |
| WO2013170971A1 (en) | 2013-11-21 |
| SI2849747T1 (en) | 2018-04-30 |
| DK2849747T3 (en) | 2017-12-04 |
| CN104284660A (zh) | 2015-01-14 |
| BR112014028566A2 (pt) | 2017-06-27 |
| JP2015516451A (ja) | 2015-06-11 |
| AU2013262077A1 (en) | 2015-01-22 |
| RS56788B1 (sr) | 2018-04-30 |
| HK1204938A1 (en) | 2015-12-11 |
| PL2849747T3 (pl) | 2018-03-30 |
| US8912226B2 (en) | 2014-12-16 |
| HRP20171725T1 (hr) | 2017-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015000106A2 (pt) | moduladores heterocíclicos de síntes de lipídio | |
| UY30438A1 (es) | Derivados n-sustituidos de 5-halo-4-[2-alquil-1-sustituidos-1h-imidazol-5-il]pirimidin-2-amina, composiciones-procesos para su preparacion y usos | |
| EA201491607A1 (ru) | Модуляторы толлподобных рецепторов | |
| LT2600850T (lt) | Farmacinė vaisto forma, apimanti 6'-fluor-(n-metil- arba n,n-dimetil-)-4-fenil-4',9'-dihidro-3'h-spiro[cikloheksan-1,1'-pirano[3,4,b]indol]-4-aminą, skirtą nociceptinio skausmo gydymui | |
| MY149731A (en) | Compounds | |
| IL207079A0 (en) | Derivatives of indole 2-carboxamides and azaindole 2-carboxamides substituted by a silanyle group, preparation thereof and therapeutic use thereof | |
| BR112015000578A2 (pt) | moduladores da via do complemento e usos dos mesmos | |
| CO6470846A2 (es) | Derivados aminobut´ricos sustituidos como inhibidores de neprilisina | |
| UY31918A (es) | Compuestos de pirazol inhibidores de fgfr, composiciones farmaceuticas que los comprenden, procesos para su preparacion y su uso como medicamento | |
| CR20120237A (es) | Derivados del ácido carbamoil-metil-amino-acético sustituido como inhibidores de nep novedosos | |
| DOP2012000124A (es) | Derivados de la cromenona con actividad anti-tumoral | |
| UA106636C2 (uk) | Морфолінотіазоли як позитивні алостеричні модулятори альфа 7 | |
| PL2600838T3 (pl) | Farmaceutyczna postać dawkowania zawierająca 6'-fluoro-(N-metylo- lub N,N-dimetylo)-4-fenylo-4'9'-dihydro-3'H-spiro[cykloheksano-1,1'-pirano[3,4b]indolo]-4-aminę | |
| BR112012006172A2 (pt) | derivados de alqueno oxindol e seus usos para o tratamento de obesidade, diabetes e hiperlipidemia | |
| CY1119786T1 (el) | Φαρμακευτικη συνθεση που περιλαμβανει (1r-4r)-6'-φθορο-ν,ν-διμεθυλ-4-φαινυλ-4',9'-διυδρο-3'h-σπειρο[κυκλοεξανο-1,1'-πυρανο-[3,4,β]ινδολ]-4-αμινη και ιμπουπροφενη | |
| EA201400120A1 (ru) | Кристаллический (1r,4r)-6'-фтор-n,n-диметил-4-фенил-4',9'-дигидро-3'н-спиро[циклогексан-1,1'-пирано[3,4,в]индол]-4-амин | |
| MX2014013028A (es) | Composicion farmaceutica que comprende (1r.4r)-6´-fluoro-n,n-dimet il-4-fenil-4´,9´-dihidro-3´h-espiro[ciclohexan-1,1´-pirano[3,4,b] indol]-4-amina y un nsar. | |
| CY1119887T1 (el) | ΦΑΡΜΑΚΕΥΤΙΚΗ ΜΟΡΦΗ ΔΟΣΟΛΟΓΙΑΣ ΠΟΥ ΠΕΡΙΛΑΜΒΑΝΕΙ 6'-ΦΘΟΡΟ-(Ν-ΜΕΘΥΛΟ- Ή Ν,Ν-ΔΙΜΕΘΥΛΟ-)-4-ΦΑΙΝΥΛΟ-4',9'-ΔΙΥΔΡΟ-3'Η-ΣΠΕΙΡΟ [ΚΥΚΛΟΕΞΑΝΟ-1,1'-ΠΥΡΑΝΟ[3,4,b] ΙΝΔΟΛ]-4-ΑΜΙΝΗ | |
| CY1119777T1 (el) | Φαρμακευτικη συνθεση περιλαμβανουσα (1r,4r)-6'-φθοpo-n,n-διμεθυλ-4-φαινυλ-4',9'διυδρο-3'h-σπειρο[κυκλοεξανο-1,1'-πυρανο[3,4,β]ινδολ]-4-αμινη και γκαμπαπεντινοειδες | |
| CY1119825T1 (el) | Φαρμακευτικη συνθεση περιλαμβανουσα (1r,4r)-6'-φθopo-n,n-διμεθυλ-4-φαινυλ-4',9'-διυδρο-3'h-σπειρο[κυκλοεξανο-1,1'-πυρανο[3,4,β]ινδολ]-4-αμινη και ντουλοξετινη | |
| MX354685B (es) | Composición farmacéutica que comprende (1r,4r)-6'-fluoro-n,n-dimet il-4-fenil-4',9'-dihidro-3'h-espiro[ciclohexan-1,1'-pirano[3,4,b] indol]-4-amina y un oxicam. | |
| EA201401272A1 (ru) | Фармацевтическая композиция, содержащая (1r,4r)-6'-фтор-n,n-диметил-4-фенил-4',9'-дигидро-3'h-спиро[циклогексан-1,1'-пирано-[3,4,b]индол]-4-амин и парацетамол или пропацетамол | |
| EA201401267A1 (ru) | Фармацевтическая композиция, содержащая (1r,4r)-6'-фтор-n,n-диметил-4-фенил-4',9'-дигидро-3'h-спиро[циклогексан-1,1'-пирано-[3,4,b]индол]-4-амин и компонент салициловой кислоты | |
| HUE041960T2 (hu) | 6'-fluor-(N-metil- vagy N,N-dimetil-)-4-fenil-4',9'-dihidro-3'H spiro[ciklohexán-1,1'-pirano[3,4,b]indol]-4-amint tartalmazó gyógyszerészeti dózisforma nociceptív fájdalom kezelésére | |
| TH129812A (th) | การใช้ร่วมกันของสารยับยั้ง Hsp90 และเฮอร์เซพทิน |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |